Zimmer Partners LP Purchases 43,876 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Zimmer Partners LP increased its holdings in Structure Therapeutics by 77.1%, owning 100,776 shares valued at approximately $1.74 million by the end of the recent quarter.
• Structure Therapeutics received a consensus rating of "Buy" from eight investment analysts, with an average price target set at $75.71.
• After reporting negative earnings per share of ($0.36), Structure Therapeutics is projected to post an EPS of -0.82 for the current fiscal year.

Zimmer Partners LP increased its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 77.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,776 shares of the company's stock after purchasing an additional 43,876 shares during the quarter. Zimmer Partners LP owned about 0.18% of Structure Therapeutics worth $1,744,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Janus Henderson Group PLC grew its stake in shares of Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock valued at $112,816,000 after purchasing an additional 203,010 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Structure Therapeutics by 3.7% during the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after purchasing an additional 63,990 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after buying an additional 322,601 shares during the period. Readystate Asset Management LP lifted its holdings in Structure Therapeutics by 129.9% in the first quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after buying an additional 271,899 shares during the period. Finally, Invesco Ltd. lifted its holdings in Structure Therapeutics by 6.1% in the first quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after buying an additional 22,619 shares during the period. 91.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GPCR has been the topic of several analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. Lifesci Capital upgraded shares of Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. JMP Securities cut their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Guggenheim cut their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, HC Wainwright cut their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $75.71.

Structure Therapeutics Stock Up 0.7%

Shares of GPCR stock traded up $0.14 on Monday, reaching $21.05. The stock had a trading volume of 217,576 shares, compared to its average volume of 899,992. The firm's 50-day moving average is $18.90 and its two-hundred day moving average is $20.66. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -20.07 and a beta of -1.89. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $45.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.